Evaluation of the pharmacogenetics of immune recovery in treated HIV-infected patients

Bibliography

• Gaardbo JC, Hartling HJ, Gerstoft J, et al. Incomplete immune recovery in HIV infection: mechanisms, relevance for clinical care, and possible solutions. Clin Develop Immunol 2012;670957:1-17
   Google Scholar
• Battegay M, Nüesch R, Hirschel B, et al. Immunological recovery and antiretroviral therapy in HIV-1 infection. Lancet Infect Dis 2006;6:280-7
   PubMed Web of Science ®Google Scholar
• Goicoechea M, Smith DM, Liu L, et al. Determinants of CD4 T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers and cellular HIV-1 DNA. J Infect Dis 2006;194:29-37
   PubMed Web of Science ®Google Scholar
• Quirk E, McLeod H, Powderly W. The pharmacogenetics of antiretroviral therapy: a review of studies to date. Clin Infect Dis 2004;39:98-106
   PubMed Web of Science ®Google Scholar
• Nakajima T, Kimura A. Genetic factors that confer sensitivity to HAART in HIV-infected subjects: implication of a benefit of an earlier initiation of HAART. Pharmacogenomics 2008;9:1347-51
   PubMed Web of Science ®Google Scholar
• Pacheco YM, Jarrín I, Del Amo J, et al. Risk factors, CD4 long-term evolution and mortality of HIV-infected patients who persistently maintain low CD4 counts, despite virological response to HAART. Curr HIV Res 2009;7:612-19
   PubMed Web of Science ®Google Scholar
• Loutfy MR, Genebat M, Moore D, et al. A CD4+ cell count < 200 cells per cubic millimeter at 2 years after initiation of combination antiretroviral therapy is associated with increased mortality in HIV-infected individuals with viral suppression. J Acquir Immune Defic Syndr 2010;55:451-9
   PubMed Web of Science ®Google Scholar
• Engsig FN, Gerstoft J, Kronborg G, et al. Long-term mortality in HIV patients virally suppressed for more than three years with incomplete CD4 recovery: a cohort study. BMC Infect Dis 2010;10:318
   PubMed Web of Science ®Google Scholar
• van Lelyveld SFL, Gras L, Kesselring A, et al. Long-term complications in patients with poor immunological recovery despite virological successful HAART in Dutch ATHENA cohort. AIDS 2012;26:465-74
   PubMed Web of Science ®Google Scholar
• Gazzola L, Tincati C, Bellistri GM, et al. The absence of CD4+ T cell count recovery despite receipt of virologically suppressive highly active antiretroviral therapy: clinical risk, immunological gaps, and therapeutic options. Clin Infect Dis 2009;48:328-37
   PubMed Web of Science ®Google Scholar
• Kelley CF, Kitchen CM, Hunt PW, et al. Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. Clin Infect Dis 2009;48:787-94
   PubMed Web of Science ®Google Scholar
• Piketty C, Castiel P, Belec L, et al. Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease. AIDS 1998;12:745-50
   PubMed Web of Science ®Google Scholar
• Johnson M, Sabin C, Girardi E. Definition and epidemiology of late presentation in Europe. Antivir Ther 2010;15:3-8
   PubMed Web of Science ®Google Scholar
• Molina-Pinelo S, Vallejo A, Díaz L, et al. Premature immunosenescence in HIV-infected patients on highly active antiretroviral therapy with low-level CD4 T cell repopulation. J Antimicrob Chemother 2009;64:579-88
   PubMed Web of Science ®Google Scholar
• Tanaskovic S, Fernandez S, French MA, et al. Thymic tissue is not evident on high-resolution computed tomography and [18F] Fluoro-deoxy-glucose positron emission tomography scans of aviraemic HIV patients with poor recovery of CD4+ T cells. AIDS 2011;25:1235-7
   PubMed Web of Science ®Google Scholar
• Isgrò A, Leti W, De Santis W, et al. Altered clonogenic capability and stromal cell function characterize bone marrow of HIV-infected subjects with low CD4+ T cell counts despite viral suppression during HAART. Clin Infect Dis 2008;46:1902-10
   PubMed Web of Science ®Google Scholar
• Méndez-Lagares G, García-Pergañeda A, Pozo-Balado MD, et al. Differential alterations of the CD4 and CD8 T cell subsets in HIV-infected patients on highly active antiretroviral therapy with low CD4 T cell restoration. J Antimicrob Chemother 2012;67:1228-37
   PubMed Web of Science ®Google Scholar
• Marchetti G, Gori A, Casabianca A, et al. Comparative analysis of T-cell turnover and homeostatic parameters in HIV-infected patients with discordant immune-virological responses to HAART. AIDS 2006;20:1727-36
   PubMed Web of Science ®Google Scholar
• Marziali M, De Santis W, Carello R, et al. T-cell homeostasis alteration in HIV-1 infected subjects with low CD4 T-cell count despite undetectable virus load during HAART. AIDS 2006;20:2033-41
   PubMed Web of Science ®Google Scholar
• Resino S, Rivero L, Ruiz-Mateos E, et al. Immunity in HIV-1-infected adults with a previous state of moderate-severe immune-suppression and more than 500 CD4C T cell after highly active antiretroviral therapy. J Clin Immunol 2004;24:379-88
   PubMed Web of Science ®Google Scholar
• Diaz A, Alós L, León A, et al. Factors associated with collagen deposition in lymphoid tissue in long-term treated HIV-infected patients. AIDS 2010;24:2029-39
   Google Scholar
• Schacker TW, Nguyen PL, Beilman GJ, et al. Collagen deposition in HIV-1 infected lymphatic tissues and T cell homeostasis. J Clin Invest 2002;110:1133-9
   PubMed Web of Science ®Google Scholar
• Zeng M, Smith AJ, Wietgrefe SW, et al. Cumulative mechanisms of lymphoid tissue fibrosis and T cell depletion in HIV-1 and SIV infections. J Clin Invest 2011;121:998-1008
   PubMed Web of Science ®Google Scholar
• Méndez-Lagares G, del Pozo Balado MM, Genebat M, et al. Severe immune dysregulation affects CD4+CD25hiFoxP3+ regulatory t cells in HIV-infected patients with low-level CD4 T-cell repopulation despite suppressive highly active antiretroviral therapy. J Infect Dis 2012;205:1501-9
   PubMed Web of Science ®Google Scholar
• Almeida ARM, Legrand N, Papiernik M, et al. Homeostasis of peripheral CD4+ T Cells: IL-2Ra and IL-2 shape a population of regulatory cells That controls CD4+ T Cell numbers. J Immunol 2002;169:4850-60
   PubMed Web of Science ®Google Scholar
• Winstead CJ, Reilly CS, Moon JJ, et al. CD4+CD25+Foxp3+ regulatory T Cells optimize diversity of the conventional T cell repertoire during reconstitution from lymphopenia. J Immunol 2010;184:4749-60
   PubMed Web of Science ®Google Scholar
• Bandera A, Ferrario G, Saresella M, et al. CD4+ T cell depletion, immune activation and increased production of regulatory T cells in the thymus of HIV infected individuals. PLoS One 2010;5:e10788
   PubMedGoogle Scholar
• Marchetti G, Bellistri GM, Borghi E, et al. Microbial translocation is associated with sustained failure in CD4+ T-cell reconstitution in HIV-infected patients on long-term highly active antiretroviral therapy. AIDS 2008;22:2035-8
   Web of Science ®Google Scholar
• Massanella M, Negredo E, Pérez-Álvarez N, et al. CD4 T-cell hyperactivation and susceptibility to cell death determine poor CD4 T-cell recovery during suppressive HAART. AIDS 2010;24:959-68
   PubMed Web of Science ®Google Scholar
• Mavigner M, Delobel P, Cazabat M, et al. HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy. PLoS ONE 2009;4:e7658
   PubMed Web of Science ®Google Scholar
• Delobel P, Nugeyre MT, Cazabat M, et al. Naive T-cell depletion related to infection by X4 human immunodeficiency virus type 1 in poor immunological responders to highly active antiretroviral therapy. J Virol 2006;80:10229-36
   PubMed Web of Science ®Google Scholar
• Marchetti G, Gazzola L, Trabattoni D, et al. Skewed T-cell maturation and function in HIV-infected patients failing CD4R recovery upon long-term virologically suppressive HAART. AIDS 2010;24:1455-60
   PubMed Web of Science ®Google Scholar
• Erikstrup C, Kronborg G, Lohse N, et al. T-cell dysfunction in HIV-1-infected patients with impaired recovery of CD4 cells despite suppression of viral replication. J Acquir Immune Defic Syndr 2010;53:303-10
   PubMed Web of Science ®Google Scholar
• Grabmeier-Pfistershammer K, Steinberger P, Rieger A, et al. Identification of PD-1 as a unique marker for failing immune reconstitution in HIV-1- infected patients on treatment. J Acquir Imm Def Syndr 2011;56:118-24
   PubMedGoogle Scholar
• Benveniste O, Flahault A, Rollot F, et al. Mechanisms involved in the low-level regeneration of CD4+ cells in HIV-1-infected patients receiving highly active antiretroviral therapy who have prolonged undetectable plasma viral loads. J Infect Dis 2005;191:1670-9
   PubMed Web of Science ®Google Scholar
• Massanella M, Negredo E, Pérez-Alvarez N, et al. CD4 T-cell hyperactivation and susceptibility to cell death determine poor CD4 T-cell recovery during suppressive HAART. AIDS 2010;24:959-68
   PubMed Web of Science ®Google Scholar
• Sennepin A, Baychelier F, Guihot A, et al. NKp44L expression on CD4+ T cells is associated with impaired immunological recovery in HIV-infected patients under highly active antiretroviral therapy. AIDS 2013; Doi: 10.1097/QAD.0b013e328361a3fe
   PubMed Web of Science ®Google Scholar
• Negredo E, Massanella M, Puig J, et al. Nadir CD4 T cell count as predictor and high CD4 T cell intrinsic apoptosis as final mechanism of poor CD4 t cell recovery in virologically suppressed hiv-infected patients: clinical implications. Clin Infect Dis 2010;50:1300-8
   PubMed Web of Science ®Google Scholar
• Meroni L, Varchetta S, Manganaro D, et al. Reduced levels of CD4 cell spontaneous apoptosis in human immunodeficiency virus–infected patients with discordant response to protease inhibitors. J Infect Dis 2002;186:143-4
   PubMed Web of Science ®Google Scholar
• Wilkin TJ, Ribaudo HR, Tenorio AR, et al. The relationship of CCR5 antagonists to CD4+ T-cell gain: a meta-regression of recent clinical trials in treatment-experienced HIV-infected patients. HIV Clin Trials 2010;11:51-8
   PubMedGoogle Scholar
• Wilkin TJ, Lalama CM, McKinnon J, et al. A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4+ T-cell recovery despite sustained virologic suppression: ACTG A4256. J Infect Dis 2012;206:534-42
   PubMed Web of Science ®Google Scholar
• Abrams D, Levy Y, Losso MH, et al. Interleukin-2 therapy in patients with HIV infection. N Engl J Med 2009;361:1548-59
   PubMed Web of Science ®Google Scholar
• Weiss L, Letimier FA, Carriere M, et al. In vivo expansion of naive and activated CD4+CD25+FOXP3+ regulatory T cell populations in interleukin-2-treated HIV patients. Proc Natl Acad Sci USA 2010;107:10632-7
   PubMed Web of Science ®Google Scholar
• Markert ML, Devlin BH, Chinn IK, et al. Thymus transplantation in complete DiGeorge anomaly. Immunol Res 2009;44:61-70
   PubMed Web of Science ®Google Scholar
• The International HapMap Consortium. A haplotype map of the human genome. Nature 2005;437:1299-320
   PubMed Web of Science ®Google Scholar
• Hattersley AT, McCarthy MI. What makes a good genetic association study? Lancet 2005;366:1315-23
   PubMed Web of Science ®Google Scholar
• Arnedo M, Taffé P, Sahli R, et al. Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapy. Pharmacogenet Genomics 2007;17:755-64
   PubMed Web of Science ®Google Scholar
• Colhoun HM, McKeigue PM, Davey SG. Problems of reporting genetic associations with complex outcomes. Lancet 2003;361:865-72
   PubMed Web of Science ®Google Scholar
• Freimer NB, Sabatti C. Guidelines for association studies in Human Molecular Genetics. Hum Mol Genet 2005;14:2481-3
   PubMed Web of Science ®Google Scholar
• Tarr PE, Telenti A. Toxicogenetics of antiretroviral therapy: genetic factors that contribute to metabolic complications. Antivir Ther 2007;12:999-1013
   PubMed Web of Science ®Google Scholar
• Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006;354:610-21
   PubMed Web of Science ®Google Scholar
• Deng H, Liu R, Ellmeir W, et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996;381:661-6
   PubMed Web of Science ®Google Scholar
• Samson M, Libert F, Doranz BJ, et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 receptor gene. Nature 1996;382:722-5
   PubMed Web of Science ®Google Scholar
• Dean M, Carrington M, Winkler C, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 1996;273:1856-62
   PubMed Web of Science ®Google Scholar
• Oberlin F, Amara A, Bachelerie F, et al. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature 1996;382:833-5
   PubMed Web of Science ®Google Scholar
• Lin YI, Portales P, Segondy M, et al. CXCR4 overexpression during the course of HIV-1 infection correlates with the emergence of X4 strains. J Acquir Immune Defic Syndr 2005;39:530-6
   PubMed Web of Science ®Google Scholar
• Faure S, Meyer L, Costagliola D, et al. Rapid progression to AIDS in HIV+ individuals with a structural variant of the chemokine receptor CX3CR1. Science 2000;287:2274-7
   PubMed Web of Science ®Google Scholar
• Ahuja SK, Kulkarni H, Catano G, et al. CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals. Nat Med 2008;14:413-20
   PubMed Web of Science ®Google Scholar
• Lederman MM, Penn-Nicholson A, Cho M, Mosier D. Biology of CCR5 and its role in HIV infection and treatment. JAMA 2006;296:815-26
   PubMed Web of Science ®Google Scholar
• Blanpain C, Libert F, Vassart G, et al. CCR5 and HIV infection. Receptors Channels 2002;8:19-31
   PubMedGoogle Scholar
• de Silva E, Stumpf MP. HIV and the CCR5-Delta32 resistance allele. FEMS Microbiol Lett 2004;241:1-12
   PubMed Web of Science ®Google Scholar
• Ioannidis JPA, Rosenberg PS, Goedert JJ, et al. Effects of CCR5, CCR2-64I, and SDF-1 3'A alleles on HIV-1 disease progression: an international meta-analysis of individual-patient data. Ann Intern Med 2001;135:782-95
   PubMed Web of Science ®Google Scholar
• Hütter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 2009;360:692-8
   PubMed Web of Science ®Google Scholar
• Bratt G, Karlsson A, Leandersson AC, et al. Treatment history and baseline viral load, but not tropism of CCR-5 genetype, influence prolonged antiviral efficacy of highly active antiretroviral treatment. AIDS 1998;12:2193-202
   PubMed Web of Science ®Google Scholar
• Brumme ZL, Chan KJ, Dong W, et al. CCR5Δ32 and promoter polymorphisms are not correñated with initial virological or immunological treatment response. AIDS 2001;15:2259-66
   PubMed Web of Science ®Google Scholar
• Fellay J, Marzolini C, Meaden ER, et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter1: a pharmacogenetics study. Lancet 2002;352:30-6
   Google Scholar
• Wit FWNM, van Rij RP, Weverling GJ, et al. CC chemokine receptor 5 Δ32 and CC chemokine receptor 2 64I polymorphisms do not influence the virologic and immunologic response to antiretroviral combination therapy in human immunodeficiency virus type 1-infected patients. J Infect Dis 2002;186:1726-32
   PubMed Web of Science ®Google Scholar
• Bogner JR, Lutz B, Klein HG, et al. Association of highly active antiretroviral therapy failure with chemokine receptor 5 wild type. HIV Med 2004;5:264-72
   PubMed Web of Science ®Google Scholar
• Passam AM, Zafiropoulos A, Miyakis S, et al. CCR2-64I and CXCL12 3'A alleles confer a favourable prognosis to AIDS patients undergoing HAART therapy. J Clin Virol 2005;34:302-9
   PubMed Web of Science ®Google Scholar
• Puissant B, Roubinet F, Massip P, et al. Analysis of CCR5, CCR2, CX3CR1, and SDF1 polymorphisms in HIV-positive treated patients: impact on response to HAART and on peripheral T lymphocyte counts. AIDS Res Hum Retrov 2006;22:153-62
   PubMed Web of Science ®Google Scholar
• Fernandez S, Rosenow AA, James IR, et al. Recovery of CD4+ T cells in patients with a stable virologic response to antiretroviral therapy is associated wih polymorphisms of interleukin-6 and central major histocompatibility complex genes. J Acquir Immune Defic Syndr 2006;41:1-5
   PubMed Web of Science ®Google Scholar
• Laurichesse JJ, Persoz A, Theodorou I, et al. Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5Δ32 deletion. HIV Med 2007;8:213-19
   PubMed Web of Science ®Google Scholar
• Chew CSN, Cherry CL, Kamarulzaman A, et al. A longitudinal study of the effects of ART on plasma chemokine levels in Malaysian HIV patients. Dis Markers 2011;31:303-9
   PubMed Web of Science ®Google Scholar
• Valdez H, Purvis SF, Lederman MM, et al. Association of the CCR5Δ32 mutation with improved response to antiretroviral therapy. JAMA 1999;282:734
   PubMed Web of Science ®Google Scholar
• Guerin S, Meyer L, Theodorou I, et al. CCR5delta32 deletion and response to highly active antiretroviral therapy in HIV-1-infected patients. AIDS 2000;14:2788-90
   PubMed Web of Science ®Google Scholar
• Rigato PO, Hong MA, Casseb J, et al. Better CD4+ T cell recovery in Brazilian HIV-infected individuals under HAART due to cumulative carriage of SDF-1-3'A, CCR2-V64I, CCR5-D32 and CCR5-promoter 59029A/G polymorphism. Curr HIV Res 2008;6:466-73
   PubMed Web of Science ®Google Scholar
• Hendrickson SL, Jacobson LP, Nelson GW, et al. Host genetic influences on highly active antiretroviral therapy efficacy and AIDS.free survival. J Acquir Immune Defic Syndr 2008;48:263-71
   PubMed Web of Science ®Google Scholar
• Martin MP, Carrington M, Dean M, et al. CXCR4 polymorphisms and HIV-1 pathogenesis. J Acquir Immune Defic Syndr 1998;19:430
   Web of Science ®Google Scholar
• Peraire J, Broch M, Domingo P, et al. Absence of CXCR4 C-terminal polymorphisms in HIV-1-infected and uninfected Spaniards. J Acquir Immune Defic Syndr 2006;42:382-3
   PubMed Web of Science ®Google Scholar
• Viladés C, Broch M, Plana M, et al. Effect of genetic variants of CCR2 and CCL2 on the natural history of HIV-1 infection. CCL2 -2518GG is overrepresented in a cohort of Spanish HIV-1-infected subjects. J Acquir Immune Defic Syndr 2007;44:132-8
   PubMed Web of Science ®Google Scholar
• Combadiére C, Salzwedel K, Smith ED, et al. Identification of CX3CR1: a chemotactic receptor for the human CX3C chemokine fractalkine and a fusion coreceptor for HIV. J Biol Chem 1998;273:23799-804
   PubMed Web of Science ®Google Scholar
• Vidal F, Viladés C, Domingo P, et al. Spanish HIV-1-infected long-term nonprogressors of more than 15 years have an increased frequency of the CX3CR1 249I variant allele. J Acquir Immune Defic Syndr 2005;40:527-31
   PubMed Web of Science ®Google Scholar
• Brumme ZL, Dong WWY, Chan KJ, et al. Influence of polymorphisms within the CX3CR1 and MDR-1 genes on initial antiretroviral therapy response. AIDS 2003;17:201-8
   PubMed Web of Science ®Google Scholar
• Juno J, Tuff J, Choi R, et al. The role of G protein gene GNB3 C825T polymorphism in HIV-1 acquisition, progression and immune activation. Retrovirology 2012;9:1
   PubMedGoogle Scholar
• Siffert W. G protein polymorphism in hypertension, atherosclerosis and diabetes. Annu Rev Med 2005;56:17-28
   PubMed Web of Science ®Google Scholar
• Brockmeyer NH, Potthoff A, Kasper A, et al. GNB3 C825T polymorphism and response to anti-retroviral combination therapy in HIV-1-infected patients – A pilot study. Eur J Med Res 2005;10:489-94
   PubMed Web of Science ®Google Scholar
• Smith KA. Interleukin-2: inception, impact and implications. Science 1988;240:1169-76
   PubMed Web of Science ®Google Scholar
• Haas DW, Geraghty DE, Andersen J, et al. Immunogenetics of CD4 lymphocyte count recovery during antiretroviral therapy: an AIDS Clinical Trials Group Study. J Infect Dis 2006;194:1098-107
   Google Scholar
• Kwon DS, Kaufmann DE. Protective and detrimental toles of IL-10 in HIV pathogenesis. Eur Cytokine Netw 2010;21:208-14
   PubMed Web of Science ®Google Scholar
• Srestha S, Wiener HW, Aissani B, et al. Interleukin-10 (IL-10) pathway: genetic variants and outcomes of HIV-1 infection in African American adolescents. PLoS ONE 2010;5:e13384
   PubMedGoogle Scholar
• Rasajuriar R, Booth D, Solomon A, et al. Biological determinants of immune reconstitution in HIV-infected patients receiving antiretroviral therapy: the role of interleukin 7 and interleukin 7 receptor α and microbial translocation. J Infect Dis 2010;202:1254-64
   PubMed Web of Science ®Google Scholar
• Rasajuriar R, Booth DR, Goillou M, et al. The role of SNPs in the α-chain of the IL-7R gene in CD4+ T-cell recovery in HIV-infected African patients receiving suppressive HAART. Genes Immun 2012;13:83-93
   PubMed Web of Science ®Google Scholar
• Varbanov M, Espert T, Biard-Piechaczyk M. Mechanisms of CD4 T-cell depletion triggered by HIV proteins. AIDS Rev 2006;8:221-36
   PubMed Web of Science ®Google Scholar
• Aiuti F, Mezzaroma I. Failure to reconstitute CD4+ T-cell despite suppression of HIV replication under HAART. AIDS Rev 2006;8:88-97
   PubMed Web of Science ®Google Scholar
• Hotchkiss RS, Strasser A, McDunn JE, et al. Cell Death. N Engl J Med 2009;361:1570-83
   PubMed Web of Science ®Google Scholar
• Cummins NW, Badley A. Mechanisms of HIV-associated lymphocyte apoptosis. Cell Death Dis 2010;1:e99
   PubMed Web of Science ®Google Scholar
• Fernandez Larrosa PN, Croci DO, Riva DA, et al. Apoptosis resistance in HIV-1 persistently-infected cells is independent of active viral replication and involves modulation of the apoptotic mitochondrial pathway. Retrovirology 2008;5:19
   Google Scholar
• Hulgan T, Haubrich R, Riddler S, et al. European mitochondrial DNA haplogroups and metabolic changes during antiretroviral therapy in AIDS Clinical Trials Group Study A5142. AIDS 2011;25:37-47
   PubMed Web of Science ®Google Scholar
• Hendrickson SL, Lautenberger JA, Wei Chinn LW, et al. Genetic variants in nuclear-encoded mitochondrial genes influence AIDS progression. PLoS ONE 2010;9:e12862
   Google Scholar
• Nasi M, Pinti M, Bugarini R, et al. Genetic polymorphisms of Fas (CD95) and Fas ligand (CD178) influence in the rise in CD4+ T cell count after antiretroviral therapy in drug-naive HIV-positive patients. Immunogenetics 2005;57:628-35
   PubMed Web of Science ®Google Scholar
• Lugli E, Pinti M, Nasi M, et al. MMP-7 promoter polymorphisms do not influence CD4+ recovery and changes in plasma viral load during antirretroviral therapy for HIV-1 inection. Int J Immunogenet 2005;32:269-71
   PubMed Web of Science ®Google Scholar
• Grady BJ, Samuels DC, Robbins GK, et al. Mitochondrial genomics and CD4 T-cell count recovery after antiretroviral therapy initiation in AIDS Clinical Trials Group Study 384. J Acquir Immune Defic Syndr 2011;58:363-70
   PubMed Web of Science ®Google Scholar
• Guzmán-Fulgencio M, Berenguer J, Micheloud D, et al. European mitochondrial haplogroups are associated with CD4+ T-cell recovery in HIV-infected patients on combination antiretroviral therapy. J Antimicrob Chemother 2013; advance access published Jun3 7, 2013
   PubMed Web of Science ®Google Scholar
• Goulder PJ, Walker BD. HIV and HLA class I: an evolving relationship. Immunity 2012;37:426-40
   PubMed Web of Science ®Google Scholar
• Brumme ZL, Brumme CJ, Chui C, et al. Effects of human leukocyte antigen class I genetic parameters on clinical outcomes and survival after initiation of highly active antiretroviral therapy. J Infect Dis 2007;195:1694-704
   PubMed Web of Science ®Google Scholar
• Rauch A, Nolan D, Furrer H, et al. HLA-Bw4 homozygosity is associated with an impaired CD4 T cell recovery after initiation of antiretroviral therapy. Clin Infect Dis 2008;46:1921-5
   PubMed Web of Science ®Google Scholar
• Soria A, Guerini FR, Bandera A, et al. KIR-HLA genotypes in HIV-infected patients lacking immunological recovery despite effective antiretroviral therapy. PLoS ONE 2011;6(11):e27349
   PubMedGoogle Scholar
• Huisman MT, Smit JW, Schinkel AH. Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors. AIDS 2000;14:237-42
   PubMed Web of Science ®Google Scholar
• Ward B, Gorski J, Jones D, et al. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther 2003;306:287-300
   PubMed Web of Science ®Google Scholar
• Jones K, Hoggard PG, Khoo S, et al. Effect of alpha1-acid glycoprotein on the intracellular accumulation of the HIV protease inhibitors saquinavir, ritonavir and indinavir in vitro. Br J Clin Pharmacol 2001;51:99-102
   PubMed Web of Science ®Google Scholar
• Lee CG, Ramachandra M, Jeang KT, et al. Effect of ABC transporters on HIV-1 infection: inhibition of virus production by the MDR1 transporter. FASEB J 2000;14:516-22
   PubMed Web of Science ®Google Scholar
• Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA. 2000;97(7):3473-8
   Google Scholar
• Habtewold A, Amogne W, Makonnen E, et al. Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients. J Antimicrob Chemother 2011;66:2350-61
   PubMed Web of Science ®Google Scholar
• Hitzl M, Drescher S, van der Kuip H, et al. The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics 2001;11:293-8
   PubMedGoogle Scholar
• Zhu D, Taguchi-Nakamura H, Goto M, et al. Influence of single-nucleotide polymorphisms in the multidrug resistance-1 gene on the cellular export of nelfinavir and its clinical implication for highly active antiretroviral therapy. Antivir Ther 2004;9:929-35
   PubMed Web of Science ®Google Scholar
• Uttayamakul S, Likanonsakul S, Manosuthi W, et al. Influence of ABCB-1 C3435T polymorphisms on plasma nevirapine and efavirenz levels and their effects on virologic and immunological outcomes in HIV/TB co-infected Thai adults under anti-retroviral therapy. Southeast Asian J Trop Med Public Health 2012;43:78-88
   PubMed Web of Science ®Google Scholar
• Saitoh A, Singh KK, Powell CA, et al. An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children. AIDS 2005;19:371-80
   PubMed Web of Science ®Google Scholar
• Parathyras J, Gebhardt S, Hillermann-Rebello R, et al. A pharmacogenetic study of CD4 recovery in response to HIV antiretroviral therapy in two South African population groups. J Hum Genet 2009;261-5
   PubMed Web of Science ®Google Scholar
• Winzer R, Langmann P, Zilly M, et al.et al. No influence of the P-glycoprotein polymorphisms MDR1 G2677T/A and C3435T on the virological and immunological response in treatment naïve HIV-positive patients. Ann Clin Microbiol Antimicrob 2005;4:3
   PubMedGoogle Scholar
• Teng A, Foisy M. Important drug-drug interactions in HIV-infected persons on antiretroviral therapy: an update on new infections between HIV and non-HIV drugs. Curr Infect Dis Rep 2012;14:67-82
   PubMedGoogle Scholar
• Saitoh A, Sarles E, Capparelli E, et al. CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children. AIDS 2007;21:2191-9
   PubMed Web of Science ®Google Scholar
• Bélanger AS, Caron P, Harvey M, et al. Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine. Drug Metab Dispos 2009;37:1793-6
   PubMed Web of Science ®Google Scholar
• Kwara A, Lartey M, Sagoe KW, et al. CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients. AIDS 2009;23:2101-6
   PubMed Web of Science ®Google Scholar
• Nasi M, Borghi V, Pinti M, et al. MDR1 C3435T genetic polymorphism does not influence the response to antiretroviral therapy in drug-naive HIV-positive patients. AIDS 2003;17:1696-8
   PubMed Web of Science ®Google Scholar